Binimetinib showed activity in patients with BRAF- or NRAS-mutated melanoma through MAPK pathway inhibition, and genomic profiling highlighted genetic alterations of interest that could be used as potential predictive biomarkers of response to binimetinib. This evidence concerns the gene NRAS and melanoma.